Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

BackgroundPlasma cardiac biomarkers have emerged as a cost-effective diagnostic tool aimed at early identification of cardiotoxicity. Soluble urokinase plasminogen activator receptor (suPAR) is a bone marrow cell derived signaling molecule that is associated with cardiovascular disease outcomes.Obje...

Full description

Bibliographic Details
Main Authors:	Ahmad S. Manshad, Fatima A. Ballout, Jeffrey A. Borgia, Jochen Reiser, Tochukwu M. Okwuosa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	soluble urokinase plasminogen activator receptor (suPAR) myocardial global longitudinal strain speckle tracking echocardiography biomarkers cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2021.659524/full

Similar Items

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis
by: Jinjin Ma, et al.
Published: (2023-04-01)

Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study
by: Jian Chu, et al.
Published: (2024-01-01)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
by: Jan Simon Scharrenberg, et al.
Published: (2019-11-01)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
by: Rafał Nikodem Wlazeł, et al.
Published: (2023-05-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
by: Ioannis Griveas, et al.
Published: (2021-07-01)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
by: Mohamed Abd‑Ellatif El‑Patal, et al.
Published: (2022-10-01)

Prospective use of soluble urokinase plasminogen activator receptor to screen TB co-infected with HIV patient among TB patient
by: Tri Yudani Mardining Raras, et al.
Published: (2017-10-01)

The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults
by: Niklas Fabio Wohlwend, et al.
Published: (2023-09-01)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
by: Viktor Rotbain Curovic, et al.
Published: (2022-04-01)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
by: Kristian Blomberg, et al.
Published: (2021-10-01)

Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS
by: Sven H. Loosen, et al.
Published: (2024-05-01)

Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure
by: Yunyun Wang, et al.
Published: (2021-11-01)

Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis
by: Wenjuan Wu, et al.
Published: (2018-05-01)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
by: Anurag Mehta, et al.
Published: (2020-03-01)

Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection
by: Sebastian M. Klim, et al.
Published: (2024-02-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
by: Mariangela Manfredi, et al.
Published: (2023-04-01)

Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction
by: Nils A. Sörensen, et al.
Published: (2019-03-01)

suPAR as a marker of infection in acute kidney injury – a prospective observational study
by: Anna Hall, et al.
Published: (2018-08-01)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
by: Alice G. Vassiliou, et al.
Published: (2022-05-01)

Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis
by: Jing-jing Zhao, et al.
Published: (2018-05-01)

suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients
by: Jeppe Meyer, et al.
Published: (2018-02-01)

suPAR to Risk-Stratify Patients With Malaria
by: Veselina Stefanova, et al.
Published: (2022-06-01)

The predictive value of modified soluble urokinase plasminogen activator receptor (suPAR) with National Early Warning Score (NEWS) for mortality in emergency elderly patients in Japan: a prospective pilot study
by: Toshiya Mitsunaga, et al.
Published: (2023-01-01)

The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
by: Ashna A. Kumar, et al.
Published: (2022-01-01)

Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis
by: Hidi A. A. Abdellatif, et al.
Published: (2023-04-01)

Diagnostic and Prognostic Values of Serum C-reactive Protein, Procalcitonin, Soluble Urokinase Plasminogen Activator Receptor, and Neopterin Levels in Hospitalized Patients in the Intensive Care Unit with Ventilator-associated Pneumonia
by: Reyhan ÖZTÜRK, et al.
Published: (2021-12-01)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
by: Shirin Kouhpayeh, et al.
Published: (2017-01-01)

suPAR, a Circulating Kidney Disease Factor
by: Changli Wei, et al.
Published: (2021-10-01)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
by: Ran Zhu, et al.
Published: (2022-08-01)

suPAR as a prognostic biomarker in sepsis
by: Donadello Katia, et al.
Published: (2012-01-01)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
by: Salim S. Hayek, et al.
Published: (2018-05-01)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients
by: Eleni Gavriilaki, et al.
Published: (2023-12-01)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
by: Charlotte Höybye, et al.
Published: (2019-05-01)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
by: Torry A. Tucker, et al.
Published: (2021-02-01)

Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke
by: Dorota Różański, et al.
Published: (2021-12-01)

Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) StudyPlain-Language Summary
by: Alison G. Abraham, et al.
Published: (2021-09-01)

Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study
by: Toshiya Mitsunaga, et al.
Published: (2022-11-01)

Primary Focal Segmental Glomerulosclerosis: Why Are Pieces of This Puzzle Still Missing?
by: Hernán Trimarchi
Published: (2015-07-01)